DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

Recruiting

Conditions: Multiple Sclerosis

Interventions: Other: Siponimod

First Posted Date: 2021-06-21

Last Posted Date: 2024-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 867

Registration Number: NCT04933552

Locations: 🇺🇸
Novartis Investigative Site, La Jolla, California, United States

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Phase 3

Active, not recruiting

Conditions: Giant Cell Arteritis (GCA)

Interventions: Biological: Secukinumab 300 mg
Biological: Secukinumab 150 mg
Other: Placebo

First Posted Date: 2021-06-18

Last Posted Date: 2025-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 354

Registration Number: NCT04930094

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
IRIS Research and Development, Plantation, Florida, United States
🇺🇸
Sarasota Arthritis Res Ctr, Sarasota, Florida, United States

and more 6 locations

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

Phase 3

Completed

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Inclisiran

First Posted Date: 2021-06-18

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 450

Registration Number: NCT04929249

Locations: 🇺🇸
ARcare Center for Clinical Research ., Little Rock, Arkansas, United States
🇺🇸
ARcare Center for Clinical Research, Little Rock, Arkansas, United States
🇺🇸
Keck Medical Center USC ., Los Angeles, California, United States

and more 40 locations

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis (MS)

Interventions: Drug: Ofatumumab
Drug: Siponimod
Drug: Fingolimod
Other: Ofatumumab placebo
Other: Siponimod placebo
Other: Fingolimod placebo

First Posted Date: 2021-06-15

Last Posted Date: 2025-04-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 129

Registration Number: NCT04926818

Locations: 🇹🇷
Novartis Investigative Site, Samsun, Turkey
🇺🇸
Arkansas Childrens Hosp Rsch Inst, Little Rock, Arkansas, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 6 locations

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: capmatinib

First Posted Date: 2021-06-15

Last Posted Date: 2025-03-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT04926831

Locations: 🇺🇸
UCLA Oncology Hematology, La Jolla, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
Fairfax Northern Virginia Hem Onc, Fairfax, Virginia, United States

and more 3 locations

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Phase 1

Recruiting

Conditions: Myeloid Leukemia, Philadelphia Positive

Interventions: Drug: Asciminib Pediatric formulation group
Drug: Asciminib Adult formulation group

First Posted Date: 2021-06-14

Last Posted Date: 2025-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT04925479

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey
🇺🇸
Indiana UH Riley H for CIU, Indianapolis, Indiana, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Interventions: Drug: VAY736
Drug: lenalidomide

First Posted Date: 2021-05-26

Last Posted Date: 2025-04-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT04903197

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

Global Managed Access Program Cohort for Ligelizumab in CSU

Conditions: Chronic Spontaneous Urticaria

First Posted Date: 2021-05-26

Last Posted Date: 2022-05-11

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04903613

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant
Drug: Metformin XR
Drug: Dapagliflozin + metformin XR
Drug: Dapagliflozin

First Posted Date: 2021-05-24

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT04899349

Locations: 🇺🇸
Washington Uni School of Med Siteman Cancer Center, Saint Louis, Missouri, United States
🇲🇾
Novartis Investigative Site, Kuala Lumpur, Malaysia

Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: INE 963
Other: Placebo

First Posted Date: 2021-05-21

Last Posted Date: 2023-09-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT04896632

Locations: 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy